Applicant, as named in the Orange Book

Novo

Next listed expiry: Rybelsus on 2 May 2034. 9 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Rybelsus · 3 strengths semaglutide	semaglutide	213051	2 May 2034	patent
Saxenda liraglutide	liraglutide	206321	9 Jul 2037	patent
Ozempic · 6 strengths semaglutide	semaglutide	209637	10 Oct 2038	patent, carve-out possible
Rivfloza · 3 strengths nedosiran sodium	nedosiran sodium	215842	12 Oct 2038	patent
Ozempic · 3 strengths semaglutide	semaglutide	213051	1 Feb 2039	patent
Wegovy · 4 strengths semaglutide	semaglutide	218316	1 Feb 2039	patent
Wegovy Flextouch semaglutide	semaglutide	215256	13 May 2040	patent, carve-out possible
Wegovy · 10 strengths semaglutide	semaglutide	215256	17 Feb 2041	patent
Wegovy Hd semaglutide	semaglutide	215256	17 Feb 2041	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.